Literature DB >> 15547381

Hybrid of distraction osteogenesis unilateral frontal distraction and supraorbital reshaping in correction of unilateral coronal synostosis.

Kaneshige Satoh1, Nobuyuki Mitsukawa, Ryuhji Hayashi, Yoshiaki Hosaka.   

Abstract

Unicoronal synostotic plagiocephaly is routinely treated by intracranial wide frontal and bilateral supraorbital reshaping. Recent advancement of distraction osteogenesis in craniofacial surgery has extended to patients with craniosynostosis. Although a controversy remains between conventional osteotomy and reshaping and application of the distraction technique in surgical treatment of craniosynostosis, there have been several positive clinical reports on distraction techniques for nonsyndromic and syndromic craniosynostosis. Unicoronal distraction applied successfully to a case of frontal plagiocephaly has been described. The authors report a procedure: hybrid of unilateral frontal distraction and supraorbital reshaping on the affected side for frontal synostotic plagiocephaly. This procedure was conducted on four typical unicoronal synostotic plagiocephaly cases (patient age range, 9-14 months; all patients female) with successful results. No particular complications were encountered in any of the four cases with a follow-up period that ranged from 18 to 53 months.

Entities:  

Mesh:

Year:  2004        PMID: 15547381     DOI: 10.1097/00001665-200411000-00012

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Occipitofrontal switching for simultaneous correction of synostotic frontal and occipital plagiocephaly: a novel surgical technique.

Authors:  Peter Chanwoo Kim; Yong Don Kim; Dae Hwan Park
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2010-09

Review 2.  Frontal-orbital advancement for the management of anterior plagiocephaly.

Authors:  Hamilton Matushita; Nivaldo Alonso; Daniel Dante Cardeal; Fernanda de Andrade
Journal:  Childs Nerv Syst       Date:  2012-08-08       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.